NAPM/GhPA Merger Likely Ends Generic User Fees Push In 107th
Executive Summary
The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means that generic drug user fees will not be a focal point of the PDUFA reauthorization process.
You may also be interested in...
GPhA After Jaeger: Will Industry Pressures Push Firms Together Or Pull Association Apart? New CEO Must Face Down FOBs
The Generic Pharmaceutical Association's search for a new president will likely include some soul searching by the association as well
GPhA After Jaeger: Will Industry Pressures Push Firms Together Or Pull Association Apart? New CEO Must Face Down FOBs
The Generic Pharmaceutical Association's search for a new president will likely include some soul searching by the association as well
FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly